Friedman-KienA, Kaposi's sarcoma and Pneumocystis pneumonia among homosexual men—New York City and California, Morbidity and Mortality Weekly Report1981, 30(25): 305–8.
2.
Centers for Disease Control, Task Force on Acquired Immune Deficiency Syndrome, Update on acquired immune deficiency syndrome (AIDS)—United States, Morbidity and Mortality Weekly Report1982, 31(37): 507–8, 513–14.
3.
World Health Organization (hereafter “WHO”), Acquired immune deficiency syndrome (AIDS) update, Weekly Epidemiological Record1983, 58: 351.
4.
PapeJW, Characteristics of the acquired immunodeficiency syndrome (AIDS) in Haiti, New England Journal of Medicine1983, 309(16): 945–50.
5.
PiotP, Acquired immunodeficiency syndrome in a heterosexual population in Zaire, Lancet1984, 2(8394): 65–69.
6.
WHO, The acquired immunodeficiency syndrome (AIDS): Memorandum from a WHO meeting, Bulletin of the World Health Organization1985, 63(4): 667–72.
7.
WHO, AIDS and the WHO collaborating centres: Memorandum from a WHO meeting, Bulletin of the World Health Organization1985, 63(6): 1003–7.
8.
WHO, Second meeting of the WHO collaborating centres on AIDS: Memorandum from a WHO meeting, Bulletin of the World Health Organization1986, 64(1): 37–46.
9.
WHO, Workshop on AIDS in Central Africa, Bangui, Central African Republic, October 22–25, 1985, WHO/CDS/AIDS/85.1.
10.
WHO, Acquired immunodeficiency syndrome (AIDS): Plan of action for control in the African Region, Weekly Epidemiological Record1986, 61: 93–100.
11.
WHO, Acquired immunodeficiency syndrome: Resolution of the Thirty-ninth World Health Assembly, WHA39.29, May 16, 1986.
12.
DownsAMAncelleRBrunetJB, AIDS in Europe: Current trends and future predictions estimated from surveillance data, unpublished document, 1986.
13.
GeorgesAJ, Antibodies to LAV/HTLV-III in various population groups of the Central African Republic, poster presented at the International Conference on AIDS (ICA), Paris, June 23–25, 1986.
14.
MerlinM, Evaluation of the prevalence of anti-LAV/HTLV-III antibodies in the Central African population: About 12 sample surveys, poster presented at ICA, Paris, 1986.
15.
Lloyd G (PHLS Centre for Applied Microbiology and Research), Prevalence of HIV infection and AIDS in Uganda, personal communication, July 17, 1986.
16.
MannJM, HIV seroprevalence among hospital workers in Kinshasa, Zaire: Lack of association with occupational exposure, Journal of the American Medical Association1986, 256: 3099.
17.
HiraKS, The epidemiology and clinical manifestations of the acquired immune deficiency syndrome (AIDS) and its related complex (ARC) in Zambia, notes presented at ICA, Paris, 1986.
18.
BiggarRJ, The AIDS problem in Africa, Lancet1986, 1(8472): 79–83.
19.
Georges, supra note 13.
20.
SimonsenN, Longitudinal study of a cohort of HTLV-III/LAV infected prostitutes in Nairobi, notes presented at ICA, Paris, 1986.
21.
ForthalDN, AIDS in Tanzania, 1986, 14 p. (unpublished).
22.
MannJM, Sexual practices associated with LAV/HTLV-III seropositivity among female prostitutes in Kinshasa, Zaire, abstract presented at ICA, Paris, 1986.
23.
PiotP, Retrospective seroepidemiology of AIDS virus infection in Nairobi populations, abstract submitted to ICA, Paris, 1986.
24.
Redfield R (Walter Reed Army Institute of Research), Seroprevalence of HIV in Zambia, personal communication, July 8, 1986.
25.
Brun-VezinetF, LAV2 (HIV2) in AIDS and ARC patients: Clinical and virological studies, submitted for publication.
26.
KankiPJ, Science1986: 232, 238.
27.
Centers for Disease Control, Weekly surveillance report: United States AIDS activity (tables), Atlanta, Georgia, June 9, 1986.
28.
WHO Collaborating Centre on AIDS, Institut de Médecine et d'Epidémiologie africaines et tropicales, AIDS Surveillance in Europe, Report No. 10, Paris, 1986.
29.
Johns Hopkins University, Population Reports, 1986, 14(3), series L6.
30.
WHO Collaborating Centre on AIDS, supra note 28.
31.
MannJM, Surveillance for AIDS in a Central African city: Kinshasa, Zaire, Journal of the American Medical Association1986, 255(23): 3255–59.
32.
WHO Collaborating Centre on AIDS, supra note 28.
33.
Centers for Disease Control, supra note 27.
34.
WHO Collaborating Centre on AIDS, supra note 28.
35.
MannJM, Risk factors for human immunodeficiency virus seropositivity among children 1–24 months old in Kinshasa, Zaire, Lancet1986, pp. 654–57 (Sept. 20).
36.
MichelJM, Why do people like medicines? A perspective from Africa, Lancet1985, i: 210–11.
37.
QuinnTC, AIDS in Africa: An epidemiologic paradigm, Science1986, 234: 955–63.
38.
MannJM, Prevalence of HTLV-III/LAV in household contacts of patients with confirmed AIDS and controls in Kinshasa, Zaire, Journal of the American Medical Association1986, 256(6): 721–24; FriedlandGH, Lack of transmission of HTLV-III/LAV infection to household contacts of patients with AIDS or AIDS-related complex with oral candidiasis, New England Journal of Medicine1986, 314(6): 344–49; JasonJM, HTLV-III/LAV antibody and immune status of household contacts and sexual partners of persons with hemophilia, Journal of the American Medical Association1986, 255(2): 212–15.
39.
ZuckermanAJ, AIDS and insects, British Medical Journal1986, 292: 1094–95.
40.
GoedertJJ, Three-year incidence of AIDS in five cohorts of HTLV-III-infected risk group members, Science1986, 321 (February 28).
41.
WHO, Report of meeting on educational strategies for the prevention and control of AIDS, Geneva, June 17–19, 1986, AIDS/CPA/86.4.
